Is OVID or QURE more profitable?

Ovid Therapeutics has a net margin of -240.11% compared to uniQure's net margin of -1,154.42%. Ovid Therapeutics' return on equity of -22.51% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Ovid Therapeutics -240.11% -22.51% -18.67% uniQure -1,154.42% -145.81% -27.15%

Which has preferable earnings & valuation, OVID or GENB?

Generate Biomedicines has higher revenue and earnings than Ovid Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ovid Therapeutics $7.25M 59.72 -$17.41M -$0.29 N/A Generate Biomedicines $30.30M 65.28 N/A N/A N/A

Ovid Therapeutics (OVID) Competitors

$2.32 +0.07 (+3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$2.36 +0.04 (+1.72%)

As of 07:46 PM Eastern

Compare

OVID vs. QURE, RXRX, GENB, PGEN, and TYRA

Should you buy Ovid Therapeutics stock or one of its competitors? MarketBeat compares Ovid Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ovid Therapeutics include uniQure (QURE), Recursion Pharmaceuticals (RXRX), Generate Biomedicines (GENB), Precigen (PGEN), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.

How does Ovid Therapeutics compare to uniQure?

Ovid Therapeutics (NASDAQ:OVID) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Ovid Therapeutics currently has a consensus price target of $5.13, indicating a potential upside of 120.91%. uniQure has a consensus price target of $58.92, indicating a potential upside of 20.14%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Ovid Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Ovid Therapeutics has a net margin of -240.11% compared to uniQure's net margin of -1,154.42%. Ovid Therapeutics' return on equity of -22.51% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
uniQure	-1,154.42%	-145.81%	-27.15%

In the previous week, uniQure had 62 more articles in the media than Ovid Therapeutics. MarketBeat recorded 62 mentions for uniQure and 0 mentions for Ovid Therapeutics. uniQure's average media sentiment score of 0.52 beat Ovid Therapeutics' score of 0.00 indicating that uniQure is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
uniQure	Positive

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ovid Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	59.72	-$17.41M	-$0.29	N/A
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A

Ovid Therapeutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Summary

Ovid Therapeutics beats uniQure on 10 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Ovid Therapeutics has a net margin of -240.11% compared to Recursion Pharmaceuticals' net margin of -842.95%. Ovid Therapeutics' return on equity of -22.51% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Ovid Therapeutics. MarketBeat recorded 5 mentions for Recursion Pharmaceuticals and 0 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.00 beat Recursion Pharmaceuticals' score of -0.25 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Recursion Pharmaceuticals	Neutral
Ovid Therapeutics	Neutral

Ovid Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	22.49	-$644.76M	-$1.20	N/A
Ovid Therapeutics	$7.25M	59.72	-$17.41M	-$0.29	N/A

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Recursion Pharmaceuticals presently has a consensus target price of $8.10, indicating a potential upside of 155.52%. Ovid Therapeutics has a consensus target price of $5.13, indicating a potential upside of 120.91%. Given Recursion Pharmaceuticals' higher possible upside, research analysts clearly believe Recursion Pharmaceuticals is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Recursion Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Summary

Ovid Therapeutics beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Generate Biomedicines?

Ovid Therapeutics (NASDAQ:OVID) and Generate Biomedicines (NASDAQ:GENB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Ovid Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 120.91%. Generate Biomedicines has a consensus price target of $25.40, indicating a potential upside of 64.61%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Ovid Therapeutics is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Generate Biomedicines has higher revenue and earnings than Ovid Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	59.72	-$17.41M	-$0.29	N/A
Generate Biomedicines	$30.30M	65.28	N/A	N/A	N/A

In the previous week, Generate Biomedicines had 2 more articles in the media than Ovid Therapeutics. MarketBeat recorded 2 mentions for Generate Biomedicines and 0 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.00 equaled Generate Biomedicines'average media sentiment score.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Generate Biomedicines	Neutral

Generate Biomedicines has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Generate Biomedicines' return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Generate Biomedicines	N/A	N/A	N/A

72.2% of Ovid Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ovid Therapeutics and Generate Biomedicines tied by winning 6 of the 12 factors compared between the two stocks.

How does Ovid Therapeutics compare to Precigen?

Precigen (NASDAQ:PGEN) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ovid Therapeutics has lower revenue, but higher earnings than Precigen. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	197.41	-$250.64M	-$1.18	N/A
Ovid Therapeutics	$7.25M	59.72	-$17.41M	-$0.29	N/A

Precigen currently has a consensus price target of $12.50, indicating a potential upside of 133.21%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 120.91%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Precigen had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 4 mentions for Precigen and 0 mentions for Ovid Therapeutics. Precigen's average media sentiment score of 0.56 beat Ovid Therapeutics' score of 0.00 indicating that Precigen is being referred to more favorably in the media.

Company	Overall Sentiment
Precigen	Positive
Ovid Therapeutics	Neutral

Ovid Therapeutics has a net margin of -240.11% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Precigen has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

Summary

Precigen beats Ovid Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Ovid Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Ovid Therapeutics	$7.25M	59.72	-$17.41M	-$0.29	N/A

Tyra Biosciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tyra Biosciences currently has a consensus price target of $47.00, suggesting a potential upside of 56.35%. Ovid Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 120.91%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Tyra Biosciences had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 4 mentions for Tyra Biosciences and 0 mentions for Ovid Therapeutics. Tyra Biosciences' average media sentiment score of 0.63 beat Ovid Therapeutics' score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tyra Biosciences	Positive
Ovid Therapeutics	Neutral

Tyra Biosciences has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Summary

Ovid Therapeutics beats Tyra Biosciences on 8 of the 15 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OVID vs. The Competition

Export

Metric	Ovid Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$419.94M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-8.00	19.75	24.92	23.97
Price / Sales	59.72	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.32	8.29	10.79	6.50
Net Income	-$17.41M	$23.85M	$3.56B	$336.88M
7 Day Performance	-1.69%	5.21%	1.67%	-0.22%
1 Month Performance	-6.07%	2.19%	0.43%	0.77%
1 Year Performance	700.00%	60.99%	32.84%	31.57%

Ovid Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OVID Ovid Therapeutics	2.1299 of 5 stars	$2.32 +3.1%	$5.13 +120.9%	+624.9%	$419.94M	$7.25M	N/A	60	Gap Down
QURE uniQure	2.6904 of 5 stars	$27.10 -2.8%	$42.83 +58.1%	+212.4%	$1.71B	$16.10M	N/A	500	Trending News Insider Trade
RXRX Recursion Pharmaceuticals	3.1519 of 5 stars	$3.19 -3.2%	$8.10 +154.3%	-36.8%	$1.69B	$74.68M	N/A	400	Gap Down
GENB Generate Biomedicines	N/A	$13.18 -3.0%	$25.40 +92.7%	N/A	$1.69B	$30.30M	N/A	312	News Coverage Gap Down
PGEN Precigen	2.9942 of 5 stars	$4.71 -2.0%	$12.50 +165.7%	+271.0%	$1.68B	$9.68M	N/A	190	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OVID) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ovid Therapeutics (OVID) Competitors

OVID vs. QURE, RXRX, GENB, PGEN, and TYRA

How does Ovid Therapeutics compare to uniQure?

Summary

How does Ovid Therapeutics compare to Recursion Pharmaceuticals?

Summary

How does Ovid Therapeutics compare to Generate Biomedicines?

Summary

How does Ovid Therapeutics compare to Precigen?

Summary

How does Ovid Therapeutics compare to Tyra Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ovid Therapeutics (OVID) Competitors

OVID vs. QURE, RXRX, GENB, PGEN, and TYRA

How does Ovid Therapeutics compare to uniQure?

Do analysts recommend OVID or QURE?

Is OVID or QURE more profitable?

Does the media prefer OVID or QURE?

Do institutionals & insiders believe in OVID or QURE?

Which has higher earnings and valuation, OVID or QURE?

Which has more risk and volatility, OVID or QURE?

Summary

How does Ovid Therapeutics compare to Recursion Pharmaceuticals?

Is RXRX or OVID more profitable?

Does the media favor RXRX or OVID?

Which has stronger valuation and earnings, RXRX or OVID?

Do insiders & institutionals hold more shares of RXRX or OVID?

Do analysts prefer RXRX or OVID?

Which has more risk and volatility, RXRX or OVID?

Summary

How does Ovid Therapeutics compare to Generate Biomedicines?

Do analysts prefer OVID or GENB?

Which has preferable earnings & valuation, OVID or GENB?

Does the media refer more to OVID or GENB?

Is OVID or GENB more profitable?

Do institutionals and insiders believe in OVID or GENB?

Summary

How does Ovid Therapeutics compare to Precigen?

Do insiders & institutionals believe in PGEN or OVID?

Which has higher valuation & earnings, PGEN or OVID?

Do analysts recommend PGEN or OVID?

Does the media favor PGEN or OVID?

Is PGEN or OVID more profitable?

Which has more risk & volatility, PGEN or OVID?

Summary

How does Ovid Therapeutics compare to Tyra Biosciences?

Which has preferable valuation and earnings, TYRA or OVID?

Which has more risk & volatility, TYRA or OVID?

Do insiders and institutionals hold more shares of TYRA or OVID?

Do analysts rate TYRA or OVID?

Does the media prefer TYRA or OVID?

Is TYRA or OVID more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools